Current oncology最新文献

{"title":"The Objective Response and Disease Control Rates in Patients with Liver Metastastic Breast Cancer Receiving Transarterial Radioembolization: A Meta-Analysis.","authors":"Natale Quartuccio, Vincenzo Militano, Marco Pappalardo, Luca Filippi, Oreste Bagni, Antonino Maria Moreci, Salvatore Ialuna","doi":"10.3390/curroncol31110508","DOIUrl":"10.3390/curroncol31110508","url":null,"abstract":"<p><strong>Aim: </strong>To meta-analyze the utility of transarterial radioembolization (TARE) in patients with liver metastatic breast cancer (BC), based on the objective response rate (ORR) and disease control rate (DCR).</p><p><strong>Methods: </strong>A literature search was performed retrieving studies with (1) at least 10 patients with liver metastatic BC treated with TARE and (2) adequate information to derive ORR and DCR. The ORR is the ratio between patients with liver lesions showing complete response (CR) or partial response (PR) over the total number of patients treated with TARE; the DCR is the ratio between patients with CR, PR, or stable disease (SD) over the total number of patients treated with TARE.</p><p><strong>Results: </strong>Eighteen studies (650 patients) were eligible; the ORR of TARE resulted 50.71% (95% C.I.: 40.04-61.36) and the DCR resulted 88.37% (95% C.I.: 81.89-93.57). Taking into account resin spheres (395 patients), the ORR was 60.35% (95% C.I.: 46.55-73.36) and the DCR was 92.73% (95% C.I.: 87.17-96.80%). Considering glass spheres (144 patients), the ORR was 32.38% (95% C.I.: 18.43-48.16) and the DCR was 82.69% (95% C.I.: 59.29-97.26).</p><p><strong>Conclusions: </strong>This meta-analysis favors the use of TARE in patients with liver metastatic BC either with resin or glass spheres.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6879-6890"},"PeriodicalIF":2.8,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant Pleural Effusion: Diagnosis and Treatment-Up-to-Date Perspective.","authors":"Riccardo Orlandi, Andrea Cara, Enrico Mario Cassina, Sara Degiovanni, Lidia Libretti, Emanuele Pirondini, Federico Raveglia, Antonio Tuoro, Sara Vaquer, Stefania Rizzo, Francesco Petrella","doi":"10.3390/curroncol31110507","DOIUrl":"10.3390/curroncol31110507","url":null,"abstract":"<p><p>Malignant pleural effusion is the presence of malignant cells within the pleural fluid, representing the second most common cause of pleural exudate. Although diagnostic methods and management techniques for malignant pleural effusion have dramatically improved over the decades, the current treatment is still palliative, aiming to remove pleural fluid, possibly prevent its recurrence, and alleviate symptoms through a wide range of available procedures. Treatment should be tailored to the individual patient, considering comorbidities, size of the effusion, rate of fluid accumulation, underlying cardiac or respiratory conditions, rate of recurrence, presence of loculations or trapped lung, tumor characteristics, cancer type, and patient preferences. This manuscript aims to review the available literature and to present the latest evidence on malignant pleural effusion management in order to provide an updated perspective on its diagnosis and treatment.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6867-6878"},"PeriodicalIF":2.8,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to Next Treatment Following Sub-Ablative Progression Directed Radiation Therapy for Oligoprogressive Non-Small-Cell Lung Cancer.","authors":"Riccardo Ray Colciago, Chiara Chissotti, Federica Ferrario, Maria Belmonte, Giorgio Purrello, Valeria Faccenda, Denis Panizza, Stefania Canova, Gaia Passarella, Diego Luigi Cortinovis, Stefano Arcangeli","doi":"10.3390/curroncol31110505","DOIUrl":"10.3390/curroncol31110505","url":null,"abstract":"<p><p>We aimed to evaluate whether progression-directed radiation therapy (PDRT) can prolong the initiation of a subsequent systemic therapy regimen in a cohort of patients with oligoprogressive NSCLC. A retrospective analysis was conducted on NSCLC patients who underwent PDRT for extracranial oligoprogressive NSCLC, defined as limited (up to five) progressing lesions following initial complete, partial, or stable response to systemic therapy according to REC1ST 1.1 and/or PERCIST 1.0 criteria. Cox proportional hazard regressions were performed to identify factors influencing time to next treatment (TTNT), which was considered the primary endpoint. Forty patients were analyzed. First, second, and ≥3 lines of systemic therapy were administered in 22 (58.2%), 14 (27.2%), and 4 (14.6%) cases, respectively. The median total dose was 36 Gy (range: 12-60) in five fractions (1-10), with a median biological effective dose for tumor control (BED10) of 52 Gy (26.4-151.2). After a median follow-up of 11 months (2-50), PDRT delayed further systemic therapy in 32 (80.0%) treatments. Median TTNT was not reached at 8 months (1-47) with a one-year Kaplan-Meier estimate of 81.4% (95% CI: 75.0% to 87.8%). No >grade 3 adverse event was observed. On multivariate analysis, patients with ≥3 lines of systemic therapy and/or with larger CTV volumes did not benefit from PDRT. Despite the use of sub-ablative doses, our findings show that PDRT represents an effective, safe, and viable option for oligoprogressive NSCLC. Patients irradiated early during their systemic treatment course, with a low volume of disease and nonmetastatic oligoprogression, could derive substantial benefits from PDRT.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6840-6852"},"PeriodicalIF":2.8,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Value of GINI and ALBI Grades in Esophageal Cancer Receiving Chemoradiotherapy.","authors":"Timur Koca, Busra Hasdemir, Rahmi Atıl Aksoy, Aylin Fidan Korcum","doi":"10.3390/curroncol31110504","DOIUrl":"10.3390/curroncol31110504","url":null,"abstract":"<p><p><b>Objectives:</b> The principal objective of this study was to assess the predictive efficacy of the global immune-nutrition-inflammation index (GINI) and the albumin-bilirubin (ALBI) score among patients receiving chemoradiotherapy for esophageal cancer. <b>Methods:</b> A retrospective analysis was conducted on 46 patients who received definitive or neoadjuvant radiotherapy for esophageal cancer at our institution. Blood samples were collected from these patients prior to the initiation of radiotherapy to measure the biomarkers, including the C-reactive protein (CRP), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), the global immune-nutrition-inflammation index (GINI), and the albumin-bilirubin (ALBI) grade. The predictive significance of these biomarkers for progression-free survival (PFS) and overall survival (OS) was evaluated using both univariate and multivariate Cox regression analyses. <b>Results:</b> The median follow-up time for this study was 19.5 months (range: 2.6-166.3 months). Univariate analysis revealed that the platelet count (<i>p</i> = 0.003) and monocyte count (<i>p</i> = 0.04) were significant predictors of PFS. In the multivariate analysis, only the platelet count (<i>p</i> = 0.005) remained an independent predictor of PFS. Univariate analysis demonstrated that the neutrophil count (<i>p</i> = 0.04), lymphocyte count (<i>p</i> = 0.01), NLR (<i>p</i> = 0.005), PLR (<i>p</i> = 0.004), CRP (<i>p</i> = 0.02), ALBI grade (<i>p</i> = 0.01), and GINI (<i>p</i> = 0.005) were significant predictors of OS. Multivariate analysis identified the GINI as a predictor of OS, approaching statistical significance (<i>p</i> = 0.08). <b>Conclusion:</b> The results of our study indicate that the pretreatment GINI and ALBI grades are significantly and independently associated with the OS rates in patients with esophageal cancer who are undergoing chemoradiotherapy.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6829-6839"},"PeriodicalIF":2.8,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic Swallowing Exercises in Patients with Laryngeal Cancer Who Underwent Total Laryngectomy-A Randomized Trial.","authors":"Elena Teodora Schipor-Diaconu, Raluca Grigore, Paula Luiza Bejenaru, Catrinel Beatrice Simion-Antonie, Bianca Petra Taher, Simona Andreea Rujan, Anca Ionela Cirstea, Raluca Andreea Iftimie, Ruxandra Ioana Stancalie-Nedelcu","doi":"10.3390/curroncol31110506","DOIUrl":"10.3390/curroncol31110506","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to determine the efficacy of prophylactic swallowing exercises on swallowing function in patients undergoing total laryngectomy for laryngeal cancer.</p><p><strong>Methods: </strong>The design was a randomized controlled trial set in one tertiary care academic medical center. A total of 92 patients undergoing total laryngectomy for stages III and IV laryngeal cancer performed five targeted swallowing exercises for a period of three months after their surgery, starting two weeks after the surgery. Weekly swallowing therapy sessions were held with the patients in order to encourage adherence and proper technique. The controls received no preventive exercise and were referred for swallowing treatment following the surgery, as well as radiation therapy if necessary. The Functional Oral Intake Scale (FOIS) and the Performance Status Scale for Head and Neck Cancer Patients (PSS-H&N) were used to measure swallowing function at the baseline, one week following the surgery, and three, six, nine, and twelve months following the surgery.</p><p><strong>Results: </strong>Right after the surgery, there were no statistically significant variations between the intervention and control groups in the FOIS scores (<i>p</i> value = 0.64), the Eating in Public subscale scores (<i>p</i> value = 1) and Normalcy of Diet subscale scores (<i>p</i> = 0.33) of the PSS-H&N. The scores were significantly better among the intervention patients at months 3, 6, 9, and 12 for all the scores, with <i>p</i> values smaller than 0.000.</p><p><strong>Conclusions: </strong>Although not immediately following the surgery, the patients who engaged in prophylactic swallowing exercises showed improvements in their ability to swallow at 3, 6, 9, and 12 months following their procedure.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6853-6866"},"PeriodicalIF":2.8,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detecting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions Using T2w-Derived Radiomics Feature Maps in 3T Prostate MRI.","authors":"Laura J Jensen, Damon Kim, Thomas Elgeti, Ingo G Steffen, Lars-Arne Schaafs, Matthias Haas, Lukas J Kurz, Bernd Hamm, Sebastian N Nagel","doi":"10.3390/curroncol31110503","DOIUrl":"10.3390/curroncol31110503","url":null,"abstract":"<p><p>Prostate Imaging Reporting and Data System version 2.1 (PI-RADS) category 3 lesions are a challenge in the clinical workflow. A better detection of the infrequently occurring clinically significant prostate cancer (csPCa) in PI-RADS 3 lesions is an important objective. The purpose of this study was to evaluate if feature maps calculated from T2-weighted (T2w) 3 Tesla (3T) MRI can help detect csPCa in PI-RADS category 3 lesions. In-house biparametric 3T prostate MRI examinations acquired between January 2019 and June 2023 because of elevated prostate-specific antigen (PSA) levels were retrospectively screened. Inclusion criteria were a PI-RADS 3 lesion and available results of an ultrasound-guided targeted and systematic biopsy. Exclusion criteria were a simultaneous PI-RADS category 4 or 5 lesion and hip replacement. Target lesions with the International Society of Urological Pathology (ISUP) grade group 1 were rated clinically insignificant PCa (ciPCa) and ≥2 csPCa. This resulted in 52 patients being included in the final analysis, of whom 11 (21.1%), 8 (15.4%), and 33 (63.5%) patients had csPCa, ciPCa, and no PCa, respectively, with the latter two groups being combined as non-csPCa. Eight of the csPCas were located in the peripheral zone (PZ) and three in the transition zone (TZ). In the non-csPCa group, 29 were located in the PZ and 12 in the TZ. Target lesions were marked with volumes of interest (VOIs) on axial T2w images. Axial T2w images were then converted to 93 feature maps. VOIs were copied into the maps, and feature quantity was retrieved directly. Features were tested for significant differences with the Mann-Whitney U-test. Univariate models for single feature performance and bivariate models implementing PSA density (PSAD) were calculated. Ten map-derived features differed significantly between the csPCa and non-csPCa groups (AUCs: 0.70-0.84). The diagnostic performance for TZ lesions (AUC: 0.83-1.00) was superior to PZ lesions (AUC: 0.74-0.85). In the bivariate models, performance in the PZ improved with AUCs >0.90 throughout. Parametric feature maps alone and as bivariate models with PSAD can (?) noninvasively identify csPCa in PI-RADS 3 lesions and could serve as a quantitative tool reducing ambiguity in PI-RADS 3 lesions.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6814-6828"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pattern Anlysis of Risk-Reducing Strategies in Unaffected Korean <i>BRCA1/2</i> Mutation Carriers.","authors":"Dabin Kim, Jai Min Ryu, Sang-Ah Han, Zisun Kim, Sung-Won Kim","doi":"10.3390/curroncol31110499","DOIUrl":"10.3390/curroncol31110499","url":null,"abstract":"<p><p>The lifetime risk of breast and ovarian cancer increases substantially for individuals with mutations in <i>BRCA1/2</i>. The evidence indicates that <i>BRCA1/2</i> mutation carriers benefit from early cancer detection and prevention strategies. However, data on the patterns of risk-reducing interventions are lacking. This study investigated the patterns of surveillance and risk-reducing interventions among unaffected <i>BRCA1/2</i> mutation carriers. A cohort of unaffected <i>BRCA1/2</i> mutation carriers was identified from the Korean Hereditary Breast cAncer (KOHBRA) study database, and a telephone survey was conducted. The survey included questions on the incidence of new cancers, patterns of cancer (breast, ovarian, prostate, other) surveillance, chemoprevention, risk-reducing surgery, and reasons for participating in risk-reducing strategies. Between November 2016 and November 2020, 192 <i>BRCA1/2</i> mutation carriers were contacted, of which 83 responded. After excluding 37 responders who refused to participate, 46 participants (15 males, 31 females) were included in the analysis. The mean ± SD follow-up time was 103 ± 17 months (median 107, range 68~154), and the mean ± SD age was 31 ± 8 years. Ten <i>BRCA1/2</i> mutation carriers developed breast cancer, one developed ovarian cancer, and three developed other cancers. Six <i>BRCA1/2</i> mutation carriers (19.4%) underwent annual breast cancer surveillance as recommended by guidelines, while none underwent ovarian or prostate cancer surveillance. Three carriers (9.7%) used chemoprevention for breast cancer. Risk-reducing salpingo-oophorectomy was performed on only one <i>BRCA1/2</i> mutation carrier. The rates of breast/ovarian cancer surveillance, chemoprevention, and risk-reducing surgery were low among unaffected Korean <i>BRCA1/2</i> mutation carriers. Given this cohort's relatively high risk of developing breast cancer, strategies to encourage active participation in risk reduction are needed.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6767-6777"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing Underscreening for Cervical Cancer among South Asian Women: Using Concept Mapping to Compare Service Provider and Service User Perspectives of Cervical Screening in Ontario, Canada.","authors":"Kimberly A Devotta, Patricia O'Campo, Jacqueline L Bender, Aisha K Lofters","doi":"10.3390/curroncol31110498","DOIUrl":"10.3390/curroncol31110498","url":null,"abstract":"<p><p>Cervical cancer is largely preventable through screening and treatment of cervical lesions. In the province of Ontario, South Asian women have some of the lowest rates of screening. The roles of service providers-those in healthcare and community services-and their interactions with screen-eligible people can greatly impact the uptake of screening. In our study, we used concept mapping (CM) to engage over 70 South Asian service users (i.e., those eligible for cervical screening) and service providers to identify a range of ideas and experiences that impact uptake of cervical screening for South Asian women, which were then rated by 45 participants in terms of 'importance' and 'ease to address' to encourage participation in cervical screening. Overall, ideas related to knowledge and education were rated as most important and easiest to address by both groups. Some differences were seen with South Asian service users valuing the importance of addressing 'cultural beliefs and influences specific to sexual health' more than service providers, while service providers valued the importance of addressing 'lack of comfort and supportive relationships' more than South Asian service users. Future interventions should target the knowledge and education needs of service users and increase service providers' awareness of cultural beliefs and influences specific to sexual health.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6749-6766"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11593261/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study.","authors":"Sercan Ön, Barış Köksal, Zafer Arık, Burcu Caner, Duygu Ercan Uzundal, Ozan Yazıcı, Burcu Arslan Benli, Eda Eylemer Mocan, Can Güngör, Zeynep Gülsüm Güç, Seval Akay, Merve Keskinkılıç, Hande Dik Avcı, Burçak Karaca Yayla, Burcu Çakar, Ulus Ali Şanlı","doi":"10.3390/curroncol31110502","DOIUrl":"10.3390/curroncol31110502","url":null,"abstract":"<p><p>(1) Background: Metastatic L-type sarcomas (liposarcoma and leiomyosarcoma) are rare and have a poor prognosis. Trabectedin is an effective agent that can be used after anthracyclines. This study was designed to evaluate the real-life effectiveness and safety of trabectedin. (2) Methods: A retrospective multicenter study was conducted on patients who were treated with trabectedin for metastatic L-type sarcomas at ten tertiary oncology centers between 2015 and 2023. The objective response rate (ORR), disease control rate (DCR), time to treatment failure (TTF), and overall survival (OS) were evaluated in the cohort. Cox regression analysis was used to determine prognostic factors for survival. (3) Results: A total of 98 patients (52% liposarcoma and 48% leiomyosarcoma) were included in the study. The median treatment line was three (range: 1 to 6). Thirteen patients (13.3%) underwent local treatment due to oligoprogression, and dose reduction was required in seventeen patients (17.3%) due to toxicity. The ORR and DCR were 16% and 42%, respectively. The median TTF was 3 months, and the median OS was 10 months. In univariate analysis, a significantly longer median TTF was observed in patients who underwent local treatment (<i>p</i> = 0.008), obtained objective responses (<i>p</i> < 0.001), and underwent dose reduction (<i>p</i> = 0.002). No statistical differences were observed according to the histologic subtype and metastatic site. In the multivariate analysis for OS, it was found that obtaining an objective response was a good prognostic factor (<i>p</i> = 0.003), while the presence of liver metastases was associated with a poor prognosis (<i>p</i> = 0.016). (4) Conclusion: Trabectedin is a suitable option for L-type sarcoma after doxorubicin-based treatments. Survival was not worse in patients who underwent dose reduction. The use of local therapies simultaneously with trabectedin can be effective.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6803-6813"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Radiotherapy Management of Extensive-Stage Small-Cell Lung Cancer in the Immunotherapy Era: An Italian National Survey on Behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).","authors":"Alessio Bruni, Vieri Scotti, Maria Alessia Zerella, Federica Bertolini, Jessica Imbrescia, Emanuela Olmetto, Chiara Bennati, Francesco Cuccia, Marianna Miele, Niccolò Giaj-Levra, Marcello Tiseo, Patrizia Ciammella, Stefano Vagge, Marco Galaverni, Antonio Pontoriero, Serena Badellino, Ruggero Spoto, Emanuele Alì, Paolo Borghetti","doi":"10.3390/curroncol31110501","DOIUrl":"10.3390/curroncol31110501","url":null,"abstract":"<p><strong>Background: </strong>Extensive-stage small-cell lung cancer (ES-SCLC) treatment has recently been revolutionized by the advent of immune checkpoint inhibitors. This survey was conducted to evaluate the current pattern of care among Italian clinicians, in particular about the integration with radiation therapy (RT).</p><p><strong>Methods: </strong>In June 2023, 225 Italian cancer care professionals were invited to complete a 21-question web-based survey about ES-SCLC management through personal contacts and the Italian Association for Radiotherapy and Clinical Oncology (AIRO) network.</p><p><strong>Results: </strong>We received 90 responses; the majority were radiation oncologists (89%) with more than 10 years of experience (51%). The preferred management of ES-SCLC in patients with a good performance status was concomitant chemo-immunotherapy (84%). Almost all respondents recommended prophylactic cranial irradiation (PCI) (85%), taking into account age and thoracic response; PCI was performed mainly between the end of chemotherapy and before starting immunotherapy (37%), with a three-dimensional conformal technique (46%). Furthermore, 83% of respondents choose to deliver thoracic RT in the case of both an intrathoracic and extrathoracic response, with an RT schedule of 30 Gy/10 fractions. Stereotactic RT is increasingly being used in oligoprogressions.</p><p><strong>Conclusions: </strong>Our analysis showed the variability of real-world management of ES-SCLC. Future clinical trials and developments are needed to improve the multidisciplinary treatment of these patients.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6791-6802"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142726699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}